Immune monitoring of islet and pancreas transplant recipients

Current Diabetes Reports

Volumn 13, Issue 5, 2013, Pages 704-712

  Abreu, J R F ^a   Roep, B O ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JDRF Center for Beta Cell Therapy in Diabetes   (Belgium)

Author keywords

Autoimmune disease; Biomarkers; Immune monitoring; Islet transplantation; Pancreas transplantation; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; CD45RA ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN; ZINC TRANSPORTER;

ALLOIMMUNITY; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MIXED LYMPHOCYTE REACTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS TRANSPLANTATION; PHENOTYPE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOLOGIC MEMORY; ISLETS OF LANGERHANS TRANSPLANTATION; MONITORING, IMMUNOLOGIC; PANCREAS TRANSPLANTATION;

EID: 84884589725     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0399-3     Document Type: Article

References (48)

1. • Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51-60. Ultimate proof that insulitis in human pancreatic leasions contain islet auoreactive CD8 T cells.
2. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832-6.
3. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012;35:1436-45.
4. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060-9.
5. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep. 2011;11:345-54.
6. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity. 2010;32:468-78.
7. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med. 2001;345:1036-40.
8. Bosi E, Bottazzo GF, Secchi A, Pozza G, Shattock M, Saunders A, et al. Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation. Diabetes. 1989;38 Suppl 1:82-4.
9. Braghi S, Bonifacio E, Secchi A, Di CV, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes. 2000;49:218-24.
10. • Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59:947-57. First evidence that recuurent autoimmunity may be cause of chronic loss of function in pancreas allograft recipients.
11. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes. 1997;46:1907-10.
12. Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 Diabetes. Diabetes. 2012;62:1656-64.
13. Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De WM, Mathieu C, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes. 2009;58:2267-76.
14. • Huurman VA, Hilbrands R, Pinkse GG, Gillard P, Duinkerken G, van de Linde P, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One. 2008;3:e2435. First evidence that cellular islet autoimmunity before transplantation determines outcome, rather than islet autoantibodies at baseline. Alloreactivity to the islet donor proved secondary to recurrent islet autoimmunity.
15. Huurman VA, van der Torren CR, Gillard P, Hilbrands R, van der Meer-Prins EP, Duinkerken G, et al. Immune responses against islet allografts during tapering of immunosuppression-a pilot study in 5 subjects. Clin Exp Immunol. 2012;169:190-8.
16. Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128:23-30.
17. • Monti P, Scirpoli M, Maffi P, Ghidoli N, de Taddeo F, Bertuzzi F, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest. 2008;118:1806-14. Demonstration of homeostatic expansion by islet auoreactive memory CD8 T cells following debulking induction therapy with thymoglobulin before islet transplantation.
18. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA. 2005;102:18425-30.
19. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48:484-90.
20. Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG, et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun. 2011;37:151-9.
21. Velthuis JH, Unger WW, van der Slik AR, Duinkerken G, Engelse M, Schaapherder AF, et al. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia. 2009;52:494-503.
22. Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes. 2010;59:1721-30.
23. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest. 2003;111:217-23.
24. Unger WW, Pearson T, Abreu JR, Laban S, van der Slik AR, der Kracht SM, et al. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS One. 2012;7:e49213.
25. Abreu JR, Roep BO. Autoreactive CD8 T cells in Type 1 diabetes: implications for pathogenesis, diagnosis, disease progression, and therapeutic intervention. Diabetes Management. 2011;1:99-108.
26. Campbell PM, Salam A, Ryan EA, Senior P, Paty BW, Bigam D, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant. 2007;7:1242-8.
27. Mohanakumar T, Narayanan K, Desai N, Ramachandran S, Shenoy S, Jendrisak M, et al. A significant role for histocompatibility in human islet transplantation. Transplantation. 2006;82:180-7.
28. Olack BJ, Swanson CJ, Flavin KS, Phelan D, Brennan DC, White NH, et al. Sensitization to HLA antigens in islet recipients with failing transplants. Transplant Proc. 1997;29:2268-9.
29. Cardani R, Pileggi A, Ricordi C, Gomez C, Baidal DA, Ponte GG, et al. Allosensitization of islet allograft recipients. Transplantation. 2007;84:1413-27.
30. Kessler L, Parissiadis A, Bayle F, Moreau F, Pinget M, Froelich N, et al. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant. 2009;9:1961-6.
31. Lobo PI, Spencer C, Simmons WD, Hagspiel KD, Angle JF, Deng S, et al. Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation. Transplant Proc. 2005;37:3438-40.
32. • Campbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM, et al. High risk of sensitization after failed islet transplantation. Am J Transplant. 2007;7:2311-7. Demonstration of immunization to donor HLA after islet transplantation.
33. Roelen DL, Huurman VA, Hilbrands R, Gillard P, Duinkerken G, van der Meer-Prins PW, et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol. 2009;156:141-8.
34. Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, Pipeleers D, et al. Tolerance to kidney allograft transplanted into Type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches. Diabetologia. 1999;42:1379-80.
35. van Kampen CA, van de Linde P, Duinkerken G, van Schip JJ, Roelen DL, Keymeulen B, et al. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation. 2005;80:118-26.
36. Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant. 2009;9:382-8.
37. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53:132-44.
38. Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128:151-70.
39. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80-7.
40. Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38 Suppl 1:85-7.
41. Monti P, Scirpoli M, Rigamonti A, Mayr A, Jaeger A, Bonfanti R, et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol. 2007;179:5785-92.
42. Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun. 2005;25:303-11.
43. Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest. 2002;109:895-903.
44. Alkemade GM, Clemente-Casares X, Yu Z, Xu BY, Wang J, Tsai S, et al. Local autoantigen expression as essential gatekeeper of memory T-cell recruitment to islet grafts in diabetic hosts. Diabetes. 2012;[In press].
45. Gillard P, Huurman V, Van der Auwera B, Decallonne B, Poppe K, Roep BO, et al. Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care. 2009;32:1817-9.
46. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA. 2006;103:17444-9.
47. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol. 2010;159:338-43.
48. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol. 2007;18:2252-61.